---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-051257"
form_type: "8-K"
ticker: "MLTX"
cik: "0001821586"
company_name: "MoonLake Immunotherapeutics"
filed_at: "2021-10-04T23:59:59+00:00"
generated_at: "2026-06-28T23:31:36.146694+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Helix Acquisition Corp. announces business combination with MoonLake Immunotherapeutics; $115M PIPE

## Summary
- Helix (HLXA) to combine with MoonLake Immunotherapeutics AG, a Swiss immuno-dermatology biotech.
- PIPE of $115M at $10.00/share from investors including sponsor affiliate and existing MoonLake holders.
- Combined company to rename as MoonLake Immunotherapeutics; Helix Class B shares convert to Class A 1:1.
- Closing expected late Q4 2021/early Q1 2022, subject to shareholder approvals and minimum $150M cash condition.
- Post-closing board: 7 directors (4 designated by MoonLake, 2 by Helix, plus Jorge Santos da Silva).

## SEC filing metadata
- accession: 0001213900-21-051257
- form_type: 8-K
- ticker: MLTX
- cik: 0001821586
- company_name: MoonLake Immunotherapeutics
- filed_at: 2021-10-04T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/0001213900-21-051257-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1821586/000121390021051257/ea147872-8k_helixacq.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-051257
- JSON: https://secwatch.observer/filing/0001213900-21-051257.json
- Plain text: https://secwatch.observer/filing/0001213900-21-051257.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.